NCT01838577
Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study No drug interventions Not Available Not Available unknown_status NCT02906163
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy treatment 1 / 2 unknown_status NCT06208033
SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) treatment 0 not_yet_recruiting NCT04105153
Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC No drug interventions Not Available Not Available completed NCT04643847
A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases treatment 2 unknown_status NCT02729298
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors treatment 1 completed NCT05998993
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) No drug interventions treatment Not Available not_yet_recruiting NCT02194556
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC treatment 4 unknown_status NCT05132985
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma treatment 2 not_yet_recruiting NCT04640870
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib Not Available Not Available completed NCT03126799
A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) treatment 2 unknown_status NCT05338619
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy treatment 2 recruiting NCT06557096
CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC treatment 0 not_yet_recruiting NCT02788058
A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy treatment 2 unknown_status NCT04989322
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC treatment 2 recruiting NCT05573373
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer treatment 1 recruiting NCT04862780
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC treatment 1 / 2 active_not_recruiting NCT02125240
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma treatment 3 unknown_status NCT04464967
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers treatment 1 / 2 withdrawn NCT05110950
Endobronchial Ultrasound Needle Aspiration With and Without Suction No drug interventions diagnostic Not Available unknown_status NCT03349203
Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer treatment 2 unknown_status NCT05256290
Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations No drug interventions treatment 1 / 2 recruiting NCT05962021
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation treatment 2 not_yet_recruiting NCT06352502
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis Not Available Not Available recruiting NCT04001777
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients treatment 1 recruiting NCT05263947
Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation treatment 2 recruiting NCT04027647
Phase 2 Study of Dacomitinib in NSCLC treatment 2 active_not_recruiting NCT06287593
The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC No drug interventions treatment Not Available not_yet_recruiting NCT04504071
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations treatment 2 unknown_status NCT03749213
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer treatment 2 recruiting NCT01665417
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma treatment 4 unknown_status NCT05089916
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study treatment 2 recruiting NCT06109558
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC treatment 1 / 2 recruiting NCT04900935
Patient-centered, Optimal Integration of Survivorship and Palliative Care No drug interventions supportive_care Not Available recruiting NCT02103257
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma treatment 4 unknown_status NCT05037331
Osimertinib for Advanced EGFR-positive NSCLC Patients No drug interventions Not Available Not Available recruiting NCT05033691
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases No drug interventions treatment Not Available recruiting NCT06207292
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer No drug interventions treatment Not Available recruiting NCT04965701
First Line Osimertinib in the Real World: an Inter-regional Prospective Study Not Available Not Available completed NCT03382795
Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients No drug interventions treatment 2 unknown_status NCT05165355
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma No drug interventions treatment 2 recruiting NCT05153408
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC treatment 1 terminated NCT03904823
A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC treatment 2 unknown_status NCT03333343
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC treatment 1 active_not_recruiting NCT04824079
Keynatinib in Treated Patients With NSCLC and Brain Metastases No drug interventions treatment 2 recruiting NCT04770688
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib treatment 1 / 2 completed NCT06306456
A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC treatment 1 / 2 recruiting NCT05852990
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC treatment 3 recruiting NCT01776684
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis diagnostic Not Available unknown_status NCT04538378
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors treatment 2 recruiting NCT01795352
Retrospective Study in a NSCLC M+ p No drug interventions Not Available Not Available completed NCT04141644
Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC treatment 1 active_not_recruiting NCT04216121
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib No drug interventions Not Available Not Available recruiting NCT06102928
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation treatment Not Available recruiting NCT04619004
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer No drug interventions treatment 2 active_not_recruiting